Skip to Content

Reyvow Approval History

FDA Approved: Yes (First approved October 11, 2019)
Brand name: Reyvow
Generic name: lasmiditan
Dosage form: Tablets
Company: Eli Lilly and Company
Treatment for: Migraine

Reyvow (lasmiditan) is a serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults.

Development History and FDA Approval Process for Reyvow

DateArticle
Oct 11, 2019Approval FDA Approves Reyvow (lasmiditan), the First Serotonin (5-HT) 1F Receptor Agonist for the Acute Treatment for Migraine
May  8, 2019AAN 2019: Two New Analyses of Lasmiditan Phase 3 Studies Measured Onset of Effect and the Effect of Lasmiditan in Patients with Prior Triptan Experience
Nov 14, 2018Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine
Sep  9, 2017Lilly's Lasmiditan Significantly Reduces Pain In Patients With Migraine
Aug  4, 2017Lilly Announces Positive Results For Second Phase 3 Study Of Lasmiditan For The Acute Treatment Of Migraine
Sep  6, 2016CoLucid Pharmaceuticals Announces Achievement of Both Primary and Key Secondary Endpoints in the SAMURAI Phase 3 Pivotal Trial of Lasmiditan in Migraine
Jun  9, 2010CoLucid Pharmaceuticals, Inc. Announces Study Data Documenting Oral Efficacy of Lasmiditan (COL-144), a Selective 5-HT1F Receptor Agonist, in the Treatment of Acute Migraine Attacks
Sep  8, 2008Phase II Results of COL-144 Presented at European Headache and Migraine Trust International Congress 2008

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide